Tonix Pharmaceuticals Aktie

Tonix treated the first subject in an investigator‑initiated phase‑1 study evaluating TNX-1900, an intranasal oxytocin formulation for the treatment of craniofacial pain including migraine and trigeminal neuralgia. The study, led by Dr. Antoinette Maassen van den Brink, examines the effect on trigeminally mediated vasodilation in healthy female participants using capsaicin and electrical stimulation, and employs laser speckle contrast imaging to measure forehead blood flow. According to the report, Tonix has more liquid assets than debt and a current ratio of 7.42; the company is also advancing TNX-1900 for additional indications and distinguishes its mechanism of action from existing CGRP inhibitors. » Mere på de.investing.com

Tonix Pharmaceuticals is developing TNX-4800, a long-acting monoclonal antibody targeting the OspA protein of Borrelia burgdorferi, and plans a meeting with the FDA in 2026 to discuss Phase 2/3 options including a controlled human infection study. The GMP-manufactured investigational product is expected to be available for clinical trials in early 2027; earlier animal studies showed 95% efficacy and a Phase 1 study demonstrated safety and detectable serum concentrations for up to 12 months. Financials show a negative EBITDA of -$97.46 million but strong liquidity (current ratio 9.89) and more cash than debt, which could support the development plan. » Mere på de.investing.com

Tonix Pharmaceuticals licensed worldwide rights to TNX-4800, a long-acting human monoclonal antibody targeting the OspA surface protein of Borrelia burgdorferi for once-yearly subcutaneous prophylaxis during tick season. Phase 1 data showed safety, tolerability and a linear PK/PD effect; the company plans an adaptive Phase 2/3 study. Tonix emphasizes the large target population in endemic U.S. areas (around 70 million people), complementing its infectious disease portfolio alongside vaccine candidates for Mpox and smallpox. » Mere på de.investing.com